Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

Deepak Almeida, Thomas Ioerger, Sandeep Tyagi, Si-Yang Li, Khisimuzi Mdluli, Koen Andries, Jacques Grosset, Jim Sacchettini, Eric Nuermberger
Deepak Almeida
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Ioerger
Department of Computer Science, Texas A&M University, College Station, Texas, USAb
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Tyagi
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Si-Yang Li
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khisimuzi Mdluli
Global Alliance for TB Drug Development, New York, New York, USAc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen Andries
Janssen Pharmaceutica, Beerse, Belgiumd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Grosset
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Sacchettini
Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texase
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Nuermberger
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAa
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAf.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: enuermb@jhmi.edu
DOI: 10.1128/AAC.00753-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for treatment of multidrug-resistant tuberculosis and is currently being studied as a component of novel treatment-shortening regimens for drug-susceptible and multidrug-resistant tuberculosis. In a limited number of bedaquiline-treated patients reported to date, upward shifts of ≥4-fold in bedaquiline MIC during treatment have been attributed to non-target-based mutations in Rv0678 that putatively increase bedaquiline efflux through the MmpS5-MmpL5 pump. These mutations also confer low-level clofazimine resistance, presumably by similar mechanism. Here, we describe a new non-target-based determinant of low-level bedaquiline and clofazimine cross-resistance in Mycobacterium tuberculosis: loss-of-function mutations in pepQ (Rv2535c), a putative Xaa-Pro aminopeptidase. pepQ mutants were selected in mice by treatment with clinically relevant doses of bedaquiline, with or without clofazimine, and were shown to have bedaquiline and clofazimine MICs 4 times higher than parental H37Rv strain. Co-incubation with efflux inhibitors verapamil/reserpine lowered bedaquiline MICs against both mutant and parent strains to a level below the MIC against H37Rv in the absence of efflux pump inhibitors. However, qPCR revealed no significant differences in expression of Rv0678, mmpS5 or mmpL5 between mutant and parent strains. Complementation of a pepQ mutant with wild-type gene restored susceptibility, indicating loss of pepQ function is sufficient for reduced susceptibility both in vitro and in mice. Although the mechanism by which mutations in pepQ confer bedaquiline and clofazimine cross-resistance remains unclear, these results may have clinical implications and warrant further evaluation of clinical isolates with reduced susceptibility to either drug for mutations in this gene.

FOOTNOTES

  • ↵#Address correspondence to Eric Nuermberger, enuermb{at}jhmi.edu.
  • Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Next
Back to top
Download PDF
Citation Tools
Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
Deepak Almeida, Thomas Ioerger, Sandeep Tyagi, Si-Yang Li, Khisimuzi Mdluli, Koen Andries, Jacques Grosset, Jim Sacchettini, Eric Nuermberger
Antimicrobial Agents and Chemotherapy May 2016, AAC.00753-16; DOI: 10.1128/AAC.00753-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
Deepak Almeida, Thomas Ioerger, Sandeep Tyagi, Si-Yang Li, Khisimuzi Mdluli, Koen Andries, Jacques Grosset, Jim Sacchettini, Eric Nuermberger
Antimicrobial Agents and Chemotherapy May 2016, AAC.00753-16; DOI: 10.1128/AAC.00753-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596